Efficacy and safety of carisbamate in patients with diabetic neuropathy or postherpetic neuralgia: Results from 3 randomized, double-blind placebo-controlled trials

Pain Practice

Volumn 14, Issue 4, 2014, Pages 332-342

  Smith, Timothy ^a   Dibernardo, Allitia ^b   Shi, Yingqi ^b   Todd, Mike J ^b   Brashear, H Robert ^c   Ford, Lisa M ^b  

^a Mercy Health   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^c Janssen Alzheimer Immunotherapy   (United States)

Author keywords

Carisbamate; Diabetic peripheral neuropathy; Postherpetic neuralgia; Pregabalin

Indexed keywords

ALANINE AMINOTRANSFERASE; CARISBAMATE; HEMOGLOBIN A1C; PARACETAMOL; PLACEBO; PREGABALIN; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; CARBAMIC ACID DERIVATIVE; S-2-O-CARBAMOYL-1-O-CHLOROPHENYL-ETHANOL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETIC NEUROPATHY; DIARRHEA; DISEASE DURATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HEADACHE; HERPES ZOSTER; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INTERACTIVE VOICE RESPONSE SYSTEM; LEG PAIN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PAIN ASSESSMENT; PAIN THRESHOLD; PERIPHERAL EDEMA; PLACEBO EFFECT; POSTHERPETIC NEURALGIA; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHINOPHARYNGITIS; RISK ASSESSMENT; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VERY ELDERLY; YOUNG ADULT; ADOLESCENT; CLINICAL TRIAL; DIABETIC NEUROPATHIES; MULTICENTER STUDY; NEURALGIA, POSTHERPETIC; PAIN MEASUREMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARBAMATES; DIABETIC NEUROPATHIES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEURALGIA, POSTHERPETIC; NEUROTRANSMITTER AGENTS; PAIN MEASUREMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84897394985     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/papr.12080     Document Type: Article

References (32)

1. Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70:1630-1635.
2. Dworkin RH, Malone DC, Panarites CJ, et al. Impact of postherpetic neuralgia and painful diabetic peripheral neuropathy on health care costs. J Pain. 2010;11:360-368.
3. Dworkin RH, Gnann JW Jr, Oaklander AL, et al. Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia. J Pain. 2008;9(1 Suppl 1):S37-S44.
4. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271-2284.
5. Schmader K, Gnann JW, Watson CP. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J Infect Dis. 2008;197:S207-S215.
6. Barrett AM, Lucero MA, Le T, et al. Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a review. Pain Med. 2007;8(Suppl 2):S50-S62.
7. Boulton AJ, Malik RA, Arezzo JC, et al. Diabetic somatic neuropathies. Diabetes Care. 2004;27:1458-1486.
8. Boulton AJ, Vinik AI, Arezzo JC, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2005;28:956-962.
9. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain. 2002;18:350-354.
10. Wu CL, Raja SN. An update on the treatment of postherpetic neuralgia. J Pain. 2008;9(1 Suppl 1):S19-S30.
11. Bennett GJ, Xie XY. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain. 1988;33:87-107.
12. Kim SH, Chung JM. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain. 1992;50:355-363.
13. DD01306 DDR. Evaluation of the anti-allodynic effect of RWJ 333369 in the Chung model of neuropathic pain (DD01306). 2001.
14. DD01308. DDR. Review summary of the Porsolt & Partners Pharmacology Report Number D00.164/2: RWJ-333369 effects on neuropathic pain (Bennett Model) in the rat (p.o. administration) (DD01308). 2001.
15. Chien S, Bialer M, Solanki B, et al. Pharmacokinetic interaction study between the new antiepileptic and CNS drug RWJ-333369 and carbamazepine in healthy adults. Epilepsia. 2006;47:1830-1840.
16. Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009;83:1-43.
17. Faught E, Holmes GL, Rosenfeld WE, et al. Randomized, controlled, dose-ranging trial of carisbamate for partial-onset seizures. Neurology. 2008;71:1586-1593.
18. Sperling MR, Greenspan A, Cramer JA, et al. Carisbamate as adjunctive treatment of partial onset seizures in adults in two randomized, placebo-controlled trials. Epilepsia. 2010;51:333-343.
19. Halford JJ, Ben-Menachem E, Kwan P, et al. A randomized, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of adjunctive carisbamate treatment in patients with partial-onset seizures. Epilepsia. 2011;52:816-825.
20. Elble RJ, Biondi DM, Ascher S, et al. Carisbamate in essential tremor: brief report of a proof of concept study. Mov Disord. 2010;25:634-638.
21. Guekht AB, Korczyn A, Bondareva IB, Gusev EI. Placebo responses in randomized trials of antiepileptic drugs. Epilepsy Behav. 2009;17:64-69.
22. Cady RK, Mathew N, Diener HC, et al. Evaluation of carisbamate for the treatment of migraine in a randomized, double-blind trial. Headache. 2009;49:216-226.
23. Katz J, Finnerup NB, Dworkin RH. Clinical trial outcome in neuropathic pain: relationship to study characteristics. Neurology. 2008;70:263-272.
24. Selph S, Carson S, McDonagh M. The placebo response in neuropathic pain trials: it's not what you think. 19th Cochrane Colloquium VI International Conference on Patient Safety. Madrid; 19-22 October, 2011.
25. Cohen D, Consoli A, Bodeau N, et al. Predictors of placebo response in randomized controlled trials of psychotropic drugs for children and adolescents with internalizing disorders. J Child Adolesc Psychopharmacol. 2010;20:39-47.
26. Bridge JA, Birmaher B, Iyengar S, et al. Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder. Am J Psychiatry. 2009;166:42-49.
27. Richter RW, Portenoy R, Sharma U, et al. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain. 2005;6:253-260.
28. Rosenstock J, Tuchman M, LaMoreaux L, et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain. 2004;110:628-638.
29. Freynhagen R, Strojek K, Griesing T, et al. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain. 2005;115:254-263.
30. Chaplan SR, Eckert III WA, Carruthers NI. Drug Discovery and Development for Pain. 2011. In: Kruger L, Light AR, eds. Translational Pain Research: From Mouse to Man. Boca Raton, FL: CRC Press; 2010. http://www.ncbi.nlm.nih.gov/books/NBK57262/
31. Lesser H, Sharma U, LaMoreaux L, et al. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. 2004;63:2104-2110.
32. Frampton JE, Scott LJ. Pregabalin: in the treatment of painful diabetic peripheral neuropathy. Drugs. 2004;64:2813-2820.